Lorence Kim, Moderna’s chief financial officer, exercised 241,000 options for $3 million on Monday, filings show. He then immediately sold them for $19.8 million, creating a profit of $16.8 million.

Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 ...

2026 and 2027 Financial Updates. Moderna is expanding its cost efficiency and prioritization programs and expects estimated GAAP operating costs of $5.4 to $5.7 billion in 2026, a reduction from ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

Moderna Inc. released new details about the abrupt departure of Chief Financial Officer Jorge Gomez, saying that it didn’t know of an internal investigation by his former employer Dentsply ...

No matter what business a company is in, its financial position is important. That's true even for high-flying COVID vaccine stocks like Moderna (MRNA-1.89%). In this Motley Fool Live video ...

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates Aug. 01, 2024 6:30 AM ET Moderna, Inc. (MRNA) Q2: 2024-08-01 Earnings Summary ...

David Meline joined Moderna as Chief Financial Officer on June 4. Mr. Meline previously served as Chief Financial Officer and EVP at Amgen (Nasdaq: AMGN) from 2014 through 2019.